Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
This is a short extract from a report by CNBC. The full text stays with the publisher — follow the link to read it there.
Read at source